• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

作者信息

Strober B E, Langley R G B, Menter A, Magid M, Porter B, Fox T, Safi J, Papavassilis C

机构信息

Department of Dermatology, University of Connecticut Health Center, Farmington, CT, U.S.A.

Probity Medical Research, Waterloo, ON, Canada.

出版信息

Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22.

DOI:10.1111/bjd.16051
PMID:28991372
Abstract
摘要

相似文献

1
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.在一项对10项中重度斑块状银屑病临床研究数据的汇总分析中，司库奇尤单抗未显示出增加抑郁、焦虑或自杀倾向的风险。
Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22.
2
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.司库奇尤单抗长期安全性经验：10 项中度至重度斑块型银屑病患者的 II 期和 III 期临床研究汇总分析。
J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4. doi: 10.1016/j.jaad.2016.03.024. Epub 2016 May 12.
3
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.司库奇尤单抗在清除亚洲中重度斑块型银屑病患者的皮肤方面优于乌司奴单抗：来自 CLEAR 研究的亚组分析。
J Dermatol. 2019 Sep;46(9):752-758. doi: 10.1111/1346-8138.15004. Epub 2019 Jul 25.
4
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.司库奇尤单抗治疗斑块状银屑病患儿：两项 3 期随机临床试验的汇总安全性分析。
Am J Clin Dermatol. 2023 Sep;24(5):821-835. doi: 10.1007/s40257-023-00782-8. Epub 2023 Jun 21.
5
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.巴柳氮钠治疗过程中的精神不良事件：银屑病临床试验分析。
J Am Acad Dermatol. 2018 Jan;78(1):81-89.e5. doi: 10.1016/j.jaad.2017.08.024. Epub 2017 Oct 3.
6
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.一项评估布罗利尤单抗治疗中重度斑块状银屑病的前瞻性 III 期、随机、双盲、安慰剂对照研究。
Br J Dermatol. 2016 Aug;175(2):273-86. doi: 10.1111/bjd.14493. Epub 2016 Jun 23.
7
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.司库奇尤单抗治疗中重度头皮银屑病的疗效：一项 24 周、随机、双盲、安慰剂对照的 3b 期研究结果。
J Am Acad Dermatol. 2017 Oct;77(4):667-674. doi: 10.1016/j.jaad.2017.05.033. Epub 2017 Aug 2.
8
Biologicals in the treatment of psoriasis.生物制剂在银屑病治疗中的应用
Curr Opin Investig Drugs. 2007 Nov;8(11):939-46.
9
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.司库奇尤单抗诱导和维持治疗中重度斑块状银屑病：一项随机、双盲、安慰剂对照、Ⅱ期方案探索研究。
Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112.
10
Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.Brodalumab 治疗中重度斑块状银屑病及有色人种皮肤患者的疗效和安全性：来自 AMAGINE-2/-3 两项随机研究的汇总分析结果。
Am J Clin Dermatol. 2019 Apr;20(2):267-276. doi: 10.1007/s40257-018-0408-z.

引用本文的文献

1
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.生物制剂和小分子药物治疗中重度银屑病：关注银屑病合并症。
BioDrugs. 2023 Jan;37(1):35-55. doi: 10.1007/s40259-022-00569-z. Epub 2023 Jan 2.
2
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.白细胞介素-17A抑制剂司库奇尤单抗的安全性综述
Pharmaceuticals (Basel). 2022 Nov 7;15(11):1365. doi: 10.3390/ph15111365.
3
Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.银屑病的流行病学和合并症：一篇叙述性综述。
Front Immunol. 2022 Jun 10;13:880201. doi: 10.3389/fimmu.2022.880201. eCollection 2022.
4
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.司库奇尤单抗治疗中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎患者五年的长期安全性：汇总临床试验和上市后监测数据的更新。
Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.
5
Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.脊柱关节炎中白细胞介素-17和肿瘤坏死因子-α的免疫调节作用：聚焦于眼睛和中枢神经系统
Ther Adv Musculoskelet Dis. 2021 Jul 9;13:1759720X211025894. doi: 10.1177/1759720X211025894. eCollection 2021.
6
The Psoriasis Decision Tree.银屑病决策树
J Clin Aesthet Dermatol. 2021 Apr;14(4):14-22. Epub 2021 Apr 1.
7
Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.评估布罗达umab 在韩国人群中治疗中度至重度斑块型银屑病的疗效和安全性：一项随机、III 期、双盲、安慰剂对照研究。
J Dermatol. 2021 Jun;48(6):807-817. doi: 10.1111/1346-8138.15733. Epub 2020 Dec 29.
8
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.司库奇尤单抗改善中重度银屑病患者的焦虑和抑郁：SUPREME 研究的事后分析。
Acta Derm Venereol. 2021 Mar 31;101(3):adv00422. doi: 10.2340/00015555-3712.
9
Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer.白细胞介素-17 诱导的中性粒细胞胞外陷阱介导胰腺癌对检查点阻断的抵抗。
J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20190354.
10
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.安全性结果：依奇珠单抗在 1822.2 患者年的暴露量下的结果：3 项成年银屑病关节炎患者临床试验的综合分析。
Arthritis Res Ther. 2020 Jan 21;22(1):14. doi: 10.1186/s13075-020-2099-0.